Business Wire

Life Biosciences Acquires Lua, Pioneering AI-Driven Healthcare Platform

Del

Life Biosciences today announced it is acquiring Lua, the communication and technology platform. This bold step is intended to facilitate the creation of a proprietary artificial intelligence (AI) platform, designed to accelerate Life Biosciences’ research for novel therapies, technologies and drugs to combat age-related decline (ARD). Life Biosciences is the first and largest biotech company focused on addressing health decline due to aging as a systemic breakdown of the body, rather than a series of isolated events and conditions.

Lua is a web- and mobile-access technology platform focused on improving patient outcomes by facilitating communication between providers and patients. Within Life Biosciences, Lua’s technology will be developed into a platform that is expected to allow faster, comprehensive analysis of study data and the integration of information from scientific studies being conducted by each of the ‘Daughter companies’ within Life Biosciences’ Dream Team business model.

This capability will support all of Life Biosciences’ research to help humans and animals live longer, healthier lives, by ensuring better and faster development of drugs and other treatments. Lua’s direct-to-patient communication model is already at work with demanding healthcare providers, such as Aces ABA, Hospice Partners of America, and The Ensign Group.

“Our Daughter companies are led by the world’s most eminent researchers on age-related decline and longevity,” said Tristan Edwards, co-founder and chief executive officer of Life Biosciences. “Their work will extend into human trials, and for that reason we are thrilled to acquire the powerful Lua platform, which will be available to each of our companies as a proven system for communicating in a HIPAA-compliant environment enabling rich interactivity with a user-friendly interface.”

– Lua: Connective Platform –

“We are excited to be joining the Life Biosciences family,” said Michael DeFranco, Lua co-founder. “Lua's focus, to improve outcomes by streamlining access between healthcare providers and patients, fits perfectly with Life Biosciences’ mission to increase healthy lifespans for all. By creating real-time feedback loops, we expect to bring data-led insights to researchers in clinical trials that were not feasible earlier. We firmly believe our direct-to-consumer technology has the potential to change pet and ultimately human life as we know it.”

Lua, founded in 2010, will continue to be operated as a separate company by its co-founders, DeFranco and Jason Krigsfeld. Beyond its primary role in healthcare, the company’s platform is also available to enterprise customers in financial services, hospitality and event planning. Its intuitive and real-time architecture allows for team-based and customer-based communication.

Nick Ventresca, chief technology officer of Life Biosciences, noted, “All drug development is based upon the insightful and privacy-protective use of data and information. We will utilize the Lua platform for not only drug development, but also in the future to securely bring information to patients and caregivers around the world.”

– Life Biosciences Overview –

Life Biosciences was co-founded in 2017 by David Sinclair, PhD, a professor in the Department of Genetics at Harvard Medical School, and Tristan Edwards, who developed its innovative structure as Chapter Two in his life, after a highly successful career as a global institutional investor, working across all asset classes.

The company’s novel Daughter company business model creates the robust research ecosystem required to forge industry leadership through two investment strategies. The first is to establish new companies, thereby extending the research of visionary scientists around the world. Secondly, Life Biosciences invests in other groundbreaking firms, providing them with the resources to maximize their potential.

In addition to Lua, there are six Daughter companies working independently and together within the Life Biosciences research environment. The company provides Daughter companies with the resources required to maximize human potential, including Lua’s AI-driven data and communications platform, experienced management, drug development experience, and a 25,000 square foot, state-of-the-art vivarium, robotics and drug screening facility in Cambridge, Mass, augmented by laboratories and offices on four continents.

Co-founded in 2017 by David Sinclair, PhD, AO, and Tristan Edwards, Life Biosciences is the first and largest biotech company addressing the eight pathways of age-related decline (ARD) in totality. It has established Daughter companies around the world, led by a Dream Team of respected scientists, to independently and collaboratively attack these pathways through pioneering research and product development. The company provides Daughter companies with resources to maximize human potential, including Lua’s AI-driven data and communications platform, drug development experience, and a 25,000 square foot, state-of-the-art vivarium, robotics and drug screening facility. Life Biosciences seeks to increase healthspans for everyone, including companion animals, by addressing the systemic breakdown of the body, rather than as a series of isolated symptoms and conditions.

For more information on Life Biosciences, please visit www.lifebiosciences.com.

Contact information

Life Biosciences
Erin Foster
erinf@lifebiosciences.com
or
media@lifebiosciences.com
or
susanm@lifebiosciences.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Business Reply Wins Prestigious Oracle Excellence Award for Specialized Partner of the Year – EMEA in ERPM Cloud23.10.2018 11:00Pressemelding

Today Oracle awarded Business Reply with its 2018 Oracle Excellence Award for Specialized Partner of the Year – EMEA in ERPM Cloud. The Oracle Excellence Awards for Specialized Partner of the Year – EMEA recognizes Business Reply for their outstanding work in driving customer success with ERP Cloud offering. Oracle partners accelerate innovation and customers upgrade to the cloud. From business planning and implementation, to connectivity and data center services, Oracle PartnerNetwork (OPN) members provide the support and services needed to maximize the value of Oracle Cloud solutions for customers’ organization, and it offers its members unique opportunities to accelerate and expand their business. Business Reply is a Platinum Cloud Select level member of Oracle PartnerNetwork (OPN). Business Reply was presented the 2018 Oracle Excellence Award for Specialized Partner of the Year – EMEA in ERPM Cloud for demonstrating an outstanding and innovative solution based on Oracle products. T

Hilton Announces Innovative New Hotel Brand; ‘Motto by Hilton’ Will Deliver Affordable Style in Coveted Urban Destinations23.10.2018 11:00Pressemelding

Hilton (NYSE:HLT) today announced the launch of Motto by Hilton, its newest affordable lifestyle brand that will empower guests by giving them the freedom to create their own experiences in the world’s most sought-after cities. As Hilton approaches its 100th anniversary, it continues to pioneer the hospitality landscape with a new brand to address the needs and desires of the evolving global traveler. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181023005378/en/ Motto by Hilton Linked Rooms (Photo: Business Wire) “Hilton prides itself on being a leader in the hospitality industry and evolving with the needs of our guests,” said Christopher J. Nassetta, president and CEO, Hilton. “Innovation is in our DNA, and as we embark on our 100th year as a company, we are innovating more than ever before. With Motto by Hilton, we are bringing to market something the industry has never experienced with its flexible and affordable room

STEMCELL Submits Drug Master File for mTeSR™1, the Most Widely Published Cell Culture Medium for Human Pluripotent Stem Cells23.10.2018 10:00Pressemelding

STEMCELL Technologies announced it has filed a Type II Drug Master File (DMF) to the Food and Drug Administration (FDA) for the Cellular Therapy Ancillary Material mTeSR™1 and has been issued DMF# 18339. mTeSR™1 is an Ancillary Material used in basic and translational research to maintain and expand human pluripotent stem cells (hPSCs) in the undifferentiated state. Used in over 1500 peer-reviewed publications, mTeSR™1 is the most widely published feeder-free cell culture medium, with established protocols for applications ranging from cell line derivation to terminal differentiation. With pre-screened raw materials that ensure batch-to-batch consistency, mTeSR™1 provides robust cultures with homogeneous, undifferentiated phenotypes. “Advancing our cGMP (Current Good Manufacturing Practices) Ancillary Material suite of products is a top priority for STEMCELL. This further demonstrates to our customers that we are a trusted partner for their bench to bedside translational journey,” says

Enevate Secures Funding from LG Chem to Accelerate Fast Charge Li-Ion Battery Technology Development for Electric Vehicles23.10.2018 10:00Pressemelding

Enevate Corporation, an advanced lithium-ion (Li-ion) battery technology company, announced that LG Chem, a leading high volume battery manufacturer in South Korea, has participated in Enevate’s recent funding. This investment is a nod to the viability of Enevate’s technology which could enable Electric Vehicles (EVs) to charge in the same time as gas cars without compromise. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181023005147/en/ Enevate’s HD-Energy® Technology for EVs allows Li-ion batteries to be charged to 75 percent capacity in five minutes, while also providing higher energy densities than available for today’s current long-range EVs. They can also safely charge and discharge down to -40°C and capture more energy during regenerative braking, extending their range in cold climates. “The strategic investment from LG Chem indicates the significance of our technology because it could directly address consumer conce

Malta and Austria Are Home to the World’s Best Investment Migration Programs23.10.2018 09:00Pressemelding

The Malta Individual Investor Program is the world’s top citizenship-by-investment program and the Austria Private Residence Program is the world’s top residence-by-investment program, according to the Global Residence and Citizenship Programs 2018–2019 report, released today by global residence and citizenship advisory firm Henley & Partners. Dr. Christian H. Kälin, an international immigration and citizenship law expert and Group Chairman of Henley & Partners, says the annual report provides a systematic analysis and comprehensive benchmarking of the world’s most important programs. “It’s an invaluable tool for anyone interested in alternative residence or citizenship as well as for the professionals like private bankers and lawyers who advise them. It also provides governments with a detailed picture of the broader investment migration industry landscape and where they fit it.” Malta is followed in the citizenship program ranking by Cyprus in 2nd place, Austria in 3rd place, and Ant

Temenos Ramps up AI Efforts to Power its Digital Banking Platform23.10.2018 08:30Pressemelding

Temenos (SIX: TEMN), the banking software company, today announced during the Machine Learning Panel at Sibos that it is increasing the development of Artificial Intelligence capabilities throughout its digital banking platform. The Temenos AI initiative will enable banks to offer personalized services to customers, augment users’ decisions with data-driven machine intelligence, and maximise straight-through-processing (STP) rates for financial transactions at reduced cost with limited or no human intervention. As part of this global initiative, Temenos has just launched a Centre of Excellence for Artificial Intelligence as its innovation engine. The Temenos AI Centre of Excellence will foster a collaborative ecosystem with Temenos’ banking clients and partners to help identify and validate use cases where AI could have an immediate impact on customer experience, as well as operational excellence, and hence improve the bottom line. Temenos’ pioneering initiative will involve injecting